Epidemiology and prevention strategies of sever fever with thrombocytopenia syndrome
ZHENG Xiaojie and YANG Xin contributed equally to this article
More Information
-
摘要: 发热伴血小板减少综合征(sever fever with thrombocytopenia syndrome, SFTS)是2009年在我国首次发现的新发蜱媒传染病，由发热伴血小板减少综合征病毒(severe fever with thrombocytopenia syndrome virus, SFTSV)(又称大别班达病毒)感染引起，该病的主要临床表现包括发热、血小板和白细胞减少等，病死率高达10%~30%。中国在全球范围内的SFTS病例数量最多，且发病率呈逐年上升趋势。SFTSV主要通过蜱虫叮咬传播，SFTS患者或SFTSV感染动物的血液和体液也具有传染性。目前尚无特效药和疫苗用于治疗或预防SFTS。因此，深入研究其流行病学特征、传播途径、高危人群及影响因素尤为重要。加快药物和疫苗的研发进程、强化监测体系、提高公众意识、完善防控措施对保障人民健康和公共安全具有重大意义。
-
关键词:
- 发热伴血小板减少综合征 /
- 流行病学 /
- 监测 /
- 防控策略
Abstract: Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerged tick-borne infectious disease first discovered in China in 2009, caused by the severe fever with thrombocytopenia syndrome virus (SFTSV), also known as Dabie bandavirus. The main clinical manifestations of this disease include fever, thrombocytopenia, and leukopenia, with a high mortality rate of 10% to 30%. China has reported the highest number of cases globally, and there has been an increase in the annual incidence rate. SFTSV is primarily transmitted through tick bites, and the blood and body fluids of patients or infected animals are also contagious. Currently, there are no specific drugs or vaccines available for the treatment or prevention of this disease. Therefore, it is crucial to conduct in-depth research on its epidemiological characteristics, transmission routes, high-risk populations, and influencing factors. The development of drugs and vaccines, the strengthening of surveillance systems, the increase of public awareness, and the improving of prevention and control measures are of great significance for people's health and public safety. -
[1] Yu CY, Lin YX, Dai YX, et al. Recent research advances in the development of Dabie Banda virus vaccines[J]. PLoS Negl Trop Dis, 2024, 18(8): e0012411. DOI: 10.1371/journal.pntd.0012411. [2] Dai ZN, Peng XF, Li JC, et al. Effect of genomic variations in severe fever with thrombocytopenia syndrome virus on the disease lethality[J]. Emerg Microbes Infect, 2022, 11(1): 1672-1682. DOI: 10.1080/22221751.2022.2081617. [3] Yun SM, Park SJ, Kim YI, et al. Genetic and pathogenic diversity of severe fever with thrombocytopenia syndrome virus(SFTSV)in South Korea[J]. JCI Insight, 2020, 5(2): e129531. DOI: 10.1172/jci.insight.129531. [4] Lee K, Seok JH, Kim H, et al. Genome-informed investigation of the molecular evolution and genetic reassortment of severe fever with thrombocytopenia syndrome virus[J]. PLoS Negl Trop Dis, 2023, 17(9): e0011630. DOI: 10.1371/journal.pntd.0011630. [5] 张全福, 李建东, 姜晓林, 等. 发热伴血小板减少综合征病毒热稳定性和灭活条件初步研究[J]. 中华实验和临床病毒学杂志, 2014, 28(3): 206-208. DOI: 10.3760/cma.j.issn.1003-9279.2014.03.016.Zhang QF, Li JD, Jiang XL, et al. A primary study of the thermal stability and inactivation of severe fever with thrombocytopenia syndrome virus[J]. Chin J Exp Clin Virol, 2014, 28(3): 206-208. DOI: 10.3760/cma.j.issn.1003-9279.2014.03.016. [6] 李佳宸, 王玉娜, 赵静, 等. 发热伴血小板减少综合征流行病学研究进展[J]. 中华流行病学杂志, 2021, 42(12): 2226-2233. DOI: 10.3760/cma.j.cn112338-20210529-00439.Li JC, Wang YN, Zhao J, et al. Advances in epidemiological research on fever with thrombocytopenia syndrome[J]. Chin J Epidemiol, 2021, 42(12): 2226-2233. DOI: 10.3760/cma.j.cn112338-20210529-00439. [7] Chen C, Li P, Li KF, et al. Animals as amplification hosts in the spread of severe fever with thrombocytopenia syndrome virus: a systematic review and Meta-analysis[J]. Int J Infect Dis, 2019, 79: 77-84. DOI: 10.1016/j.ijid.2018.11.017. [8] Zhao CY, Zhang X, Si XX, et al. Hedgehogs as amplifying hosts of severe fever with thrombocytopenia syndrome virus, China[J]. Emerg Infect Dis, 2022, 28(12): 2491-2499. DOI: 10.3201/eid2812.220668. [9] Yu KM, Jeong HW, Park SJ, et al. Shedding and transmission modes of severe fever with thrombocytopenia syndrome phlebovirus in a ferret model[J]. Open Forum Infect Dis, 2019, 6(8): ofz309. DOI: 10.1093/ofid/ofz309. [10] Oshima H, Okumura H, Maeda K, et al. A patient with severe fever with thrombocytopenia syndrome(SFTS)infected from a sick dog with SFTS virus infection[J]. Jpn J Infect Dis, 2022, 75(4): 423-426. DOI: 10.7883/yoken.JJID.2021.796. [11] Miyauchi A, Sada KN, Yamamoto H, et al. Suspected transmission of severe fever with thrombocytopenia syndrome virus from a cat to a veterinarian by a single contact: a case report[J]. Viruses, 2022, 14(2): 223. DOI: 10.3390/v14020223. [12] Yamanaka A, Kirino Y, Fujimoto S, et al. Direct transmission of severe fever with thrombocytopenia syndrome virus from domestic cat to veterinary personnel[J]. Emerg Infect Dis, 2020, 26(12): 2994-2998. DOI: 10.3201/eid2612.191513. [13] Kida K, Matsuoka Y, Shimoda T, et al. A case of cat-to-human transmission of severe fever with thrombocytopenia syndrome virus[J]. Jpn J Infect Dis, 2019, 72(5): 356-358. DOI: 10.7883/yoken.JJID.2018.526. [14] Sun YL, Zhang DT, Liu H, et al. The first reported cases of severe fever with thrombocytopenia syndrome virus from domestic sick camel to humans in China[J]. Emerg Microbes Infect, 2024, 13(1): 2309990. DOI: 10.1080/22221751.2024.2309990. [15] Chen QL, Yang D, Zhang YP, et al. Transmission and mortality risk assessment of severe fever with thrombocytopenia syndrome in China: results from 11-years'study[J]. Infect Dis Poverty, 2022, 11(1): 93. DOI: 10.1186/s40249-022-01017-4. [16] Wu YX, Yang X, Leng Y, et al. Human-to-human transmission of severe fever with thrombocytopenia syndrome virus through potential ocular exposure to infectious blood[J]. Int J Infect Dis, 2022, 123: 80-83. DOI: 10.1016/j.ijid.2022.08.008. [17] Koga S, Takazono T, Ando T, et al. Severe fever with thrombocytopenia syndrome virus RNA in Semen, Japan[J]. Emerg Infect Dis, 2019, 25(11): 2127-2128. DOI: 10.3201/eid2511.190061. [18] 黄晓霞, 杜珊珊, 李阿茜, 等. 2018-2021年中国发热伴血小板减少综合征流行特征分析[J]. 中华流行病学杂志, 2024, 45(1): 112-116. DOI: 10.3760/cma.j.cn112338-20230504-00274.Huang XX, Du SS, Li AQ, et al. Epidemiological characteristics of severe fever with thrombocytopenia syndrome in China, 2018-2021[J]. Chin J Epidemiol, 2024, 45(1): 112-116. DOI: 10.3760/cma.j.cn112338-20230504-00274. [19] Huang XX, Li JD, Li AQ, et al. Epidemiological characteristics of severe fever with thrombocytopenia syndrome from 2010 to 2019 in mainland China[J]. Int J Environ Res Public Health, 2021, 18(6): 3092. DOI: 10.3390/ijerph18063092. [20] Miao D, Liu MJ, Wang YX, et al. Epidemiology and ecology of severe fever with thrombocytopenia syndrome in China, 2010-2018[J]. Clin Infect Dis, 2021, 73(11): e3851-e3858. DOI: 10.1093/cid/ciaa1561. [21] Hidaka K, Mitoma S, Norimine J, et al. Seroprevalence for severe fever with thrombocytopenia syndrome virus among the residents of Miyazaki, Japan: an epidemiological study[J]. J Infect Chemother, 2024, 30(6): 481-487. DOI: 10.1016/j.jiac.2023.11.026. [22] Miao D, Dai K, Zhao GP, et al. Mapping the global potential transmission hotspots for severe fever with thrombocytopenia syndrome by machine learning methods[J]. Emerg Microbes Infect, 2020, 9(1): 817-826. DOI: 10.1080/22221751.2020.1748521. [23] Ding FY, Ge HH, Ma T, et al. Projecting spatiotemporal dynamics of severe fever with thrombocytopenia syndrome in the mainland of China[J]. Glob Chang Biol, 2023, 29(23): 6647-6660. DOI: 10.1111/gcb.16969. [24] Seo MG, Noh BE, Lee HS, et al. Nationwide temporal and geographical distribution of tick populations and phylogenetic analysis of severe fever with thrombocytopenia syndrome virus in ticks in Korea, 2020[J]. Microorganisms, 2021, 9(8): 1630. DOI: 10.3390/microorganisms9081630. [25] 陈秋兰, 朱曼桐, 陈宁, 等. 2011-2021年全国发热伴血小板减少综合征流行特征分析[J]. 中华流行病学杂志, 2022, 43(6): 852-859. DOI: 10.3760/cma.j.cn112338-20220325-00228.Chen QL, Zhu MT, Chen N, et al. Epidemiological characteristics of severe fever with thtrombocytopenia syndrome in China, 2011-2021[J]. Chin J Epidemiol, 2022, 43(6): 852-859. DOI: 10.3760/cma.j.cn112338-20220325-00228. [26] Li P, Tong ZD, Li KF, et al. Seroprevalence of severe fever with thrombocytopenia syndrome virus in China: a systematic review and meta-analysis[J]. PLoS One, 2017, 12(4): e0175592. DOI: 10.1371/journal.pone.0175592. [27] Kim KH, Ko MK, Kim N, et al. Seroprevalence of severe fever with thrombocytopenia syndrome in southeastern Korea, 2015[J]. J Korean Med Sci, 2017, 32(1): 29-32. DOI: 10.3346/jkms.2017.32.1.29. [28] Gokuden M, Fukushi S, Saijo M, et al. Low seroprevalence of severe fever with thrombocytopenia syndrome virus antibodies in individuals living in an endemic area in Japan[J]. Jpn J Infect Dis, 2018, 71(3): 225-228. DOI: 10.7883/yoken.JJID.2017.497. [29] Kimura T, Fukuma A, Shimojima M, et al. Seroprevalence of severe fever with thrombocytopenia syndrome(SFTS)virus antibodies in humans and animals in Ehime prefecture, Japan, an endemic region of SFTS[J]. J Infect Chemother, 2018, 24(10): 802-806. DOI: 10.1016/j.jiac.2018.06.007. [30] Ye XL, Dai K, LU QB, et al. Infection with severe fever with thrombocytopenia virus in healthy population: a cohort study in a high endemic region, China[J]. Infect Dis Poverty, 2021, 10(1): 133. DOI: 10.1186/s40249-021-00918-0. [31] Sun JM, Wu HX, Lu L, et al. Factors associated with spatial distribution of severe fever with thrombocytopenia syndrome[J]. Sci Total Environ, 2021, 750: 141522. DOI: 10.1016/j.scitotenv.2020.141522. [32] Li JC, Zhao J, Li H, et al. Epidemiology, clinical characteristics, and treatment of severe fever with thrombocytopenia syndrome[J]. Infect Med, 2022, 1(1): 40-49. DOI: 10.1016/j.imj.2021.10.001. [33] 中华人民共和国卫生部. 发热伴血小板减少综合征防治指南(2010版)[J]. 中华临床感染病杂志, 2011, 4(4): 193-194. DOI: 10.3760/cma.j.issn.1674-2397.2011.04.001 .Ministry of Health of the People's Republic of China. Guidelines for the prevention and treatment of fever with thrombocytopenia syndrome(2010 Edition)[J]. Chin J Clin Infect Dis, 2011, 4(4): 193-194. DOI:10.3760/cma.j.issn.1674-2397.2011.04.001 .[34] Kobayashi Y, Kato H, Yamagishi T, et al. Severe fever with thrombocytopenia syndrome, Japan, 2013-2017[J]. Emerg Infect Dis, 2020, 26(4): 692-699. DOI: 10.3201/eid2604.191011. [35] Kim EH, Park SJ. Emerging tick-borne Dabie bandavirus: virology, epidemiology, and prevention[J]. Microorganisms, 2023, 11(9): 2309. DOI: 10.3390/microorganisms11092309. [36] Kim CM, Han MA, Yun NR, et al. Seroprevalence of severe fever with thrombocytopenia syndrome using specimens from the Korea National Health & Nutrition Examination Survey[J]. PLoS Negl Trop Dis, 2023, 17(3): e0011097. DOI: 10.1371/journal.pntd.0011097. [37] Yuan Y, Lu QB, Yao WS, et al. Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome[J]. EBioMedicine, 2021, 72: 103591. DOI: 10.1016/j.ebiom.2021.103591. [38] Li H, Zhang LK, Li SF, et al. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus(SFTSV)related fatality[J]. Cell Res, 2019, 29(9): 739-753. DOI: 10.1038/s41422-019-0214-z. [39] Wang G, Xu YL, Zhu Y, et al. Clinical efficacy of low-dose glucocorticoid therapy for critically ill patients with severe fever with thrombocytopenia syndrome: A retrospective cohort study[J]. Int J Infect Dis, 2023, 130: 153-160. DOI: 10.1016/j.ijid.2023.03.015. [40] Ge HH, Cui N, Yin XH, et al. Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: a randomized clinical trial[J]. J Infect, 2024, 89(1): 106181. DOI: 10.1016/j.jinf.2024.106181. [41] Wen S, Xu NN, Zhao LH, et al. Ruxolitinib plus standard of care in severe hospitalized adults with severe fever with thrombocytopenia syndrome(SFTS): an exploratory, single-arm trial[J]. BMC Med, 2024, 22(1): 204. DOI: 10.1186/s12916-024-03421-z. [42] Song HJ, Zou SY, Huang Y, et al. The pathogenic and clinical characteristics of severe fever with thrombocytopenia syndrome patients with co-infections[J]. Front Cell Infect Microbiol, 2023, 13: 1298050. DOI: 10.3389/fcimb.2023.1298050. [43] Zhang SF, Du J, Mi XM, et al. Rickettsia typhi infection in severe fever with thrombocytopenia patients, China[J]. Emerg Microbes Infect, 2019, 8(1): 579-584. DOI: 10.1080/22221751.2019.1599696. [44] Zhang LK, Peng XF, Wang QX, et al. CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus[J]. Sci Adv, 2023, 9(31): eadg6856. DOI: 10.1126/sciadv.adg6856. [45] Xie JY, Li H, Zhang XA, et al. Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen[J]. Nat Microbiol, 2023, 8(1): 91-106. DOI: 10.1038/s41564-022-01279-6. [46] Zhang S, Shang H, Han S, et al. Discovery and characterization of potent broadly neutralizing antibodies from human survivors of severe fever with thrombocytopenia syndrome[J]. eBioMedicine, 2025, 111: 105481. DOI: 10.1016/j.ebiom.2024.105481. [47] Wu XL, Li YL, Huang BL, et al. A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo[J]. JCI Insight, 2020, 5(13): e136855. DOI: 10.1172/jci.insight.136855. [48] Yu KM, Park SJ, Yu MA, et al. Cross-genotype protection of live-attenuated vaccine candidate for severe fever with thrombocytopenia syndrome virus in a ferret model[J]. Proc Natl Acad Sci USA, 2019, 116(52): 26900-26908. DOI: 10.1073/pnas.1914704116. [49] Kwak JE, Kim YI, Park SJ, et al. Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets[J]. Nat Commun, 2019, 10(1): 3836. DOI: 10.1038/s41467-019-11815-4. [50] Kim D, Lai CJ, Cha I, et al. Current progress of severe fever with thrombocytopenia syndrome virus(SFTSV)vaccine development[J]. Viruses, 2024, 16(1): 128. DOI: 10.3390/v16010128. [51] Lu J, Liu J, Wu Y, et al. A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses[J]. J Virol, 2024, 98(7): e0076924. DOI: 10.1128/jvi.00769-24. -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 79
- HTML全文浏览量: 17
- PDF下载量: 21
- 被引次数: 0